FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2623-2624 June 15, 2006 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We describe two cases of panniculitis apparently caused by dasatinib. In one, management after the diagnosis of the panniculitis allowed dasatinib therapy to be continued.

In the first case, a 55-year-old woman (Patient 1) presented in the chronic phase of chronic myelogenous leukemia (CML) and did not have a major cytogenetic response (defined by the presence of the Philadelphia chromosome in <35 percent of cells in metaphase) to imatinib mesylate at a dose of 800 mg daily. She was known to have the activation-loop mutation H396R, which is associated with resistance to imatinib.¹ She entered a phase . . . [Full Text of this Article]

This article has been cited by other articles:

• Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., Andreoni, F., Scapozza, L., Formelli, F., Gambacorti-Passerini, C. (2006). In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Res. 66: 11314-11322 [Abstract] [Full Text]